ストックスクリーナーアプリを入手
7.00
0.00%
0.00
前日終値:
$7.00
開ける：
$7.07
24時間の取引高:
2.59M
Relative Volume:
0.32
時価総額：
$1.13B
収益：
$847.25M
当期純損益:
$-284.86M
株価収益率:
-3.0568
EPS:
-2.29
ネットキャッシュフロー:
$-112.35M
1週間 パフォーマンス:
+2.34%
1か月 パフォーマンス:
+11.11%
6か月 パフォーマンス:
-16.67%
1年 パフォーマンス:
-53.21%
1日の値動き範囲:
$6.905
$7.08
1週間の範囲:
$6.71
$7.08
52週間の値動き範囲:
$5.01
$17.81
Novavax Inc Stock (NVAX) Company Profile
NVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.00 | 1.11B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Sell |
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Novavax Inc. Stock Analysis and ForecastTriple-digit wealth increases - PrintWeekIndia
What drives Novavax Inc. stock priceSuperior investment outcomes - Autocar Professional
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
What analysts say about Novavax Inc. stockFree Consultation - Jammu Links News
Is Novavax Inc. a good long term investmentSky-high profits - Jammu Links News
Novavax’s Latest Vaccine Study: Key Insights for Investors - TipRanks
Over 31,000 Investors Are Getting Payouts from Novavax — Check What You Might Be Missing - TradingView
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
Why Novavax Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Novavax (NVAX) Rises Higher Than Market: Key Facts - Yahoo Finance
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Novavax's Dual Vaccine Strategy: Navigating Near-Term Hurdles to Long-Term Growth Potential - AInvest
Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth (NASDAQ:NVAX) - Seeking Alpha
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet - Yahoo Finance
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors with Substantial Losses to Contact the Firm - ACCESS Newswire
(NVAX) Technical Data - news.stocktradersdaily.com
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating - MSN
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Benzinga
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Benzinga
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now? - Yahoo Finance
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease - MedCity News
Novavax Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Novavax jumps 15% on COVID shot nod, among 14 FDA approvals in May - BioWorld MedTech
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus
Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK
Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus
Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
Ruxandra Draghia-Akli, MD, PhD - Novavax
Novavax: positive results for Covid/flu vaccine - MarketScreener
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance
Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):